HUP0400369A2 - Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400369A2
HUP0400369A2 HU0400369A HUP0400369A HUP0400369A2 HU P0400369 A2 HUP0400369 A2 HU P0400369A2 HU 0400369 A HU0400369 A HU 0400369A HU P0400369 A HUP0400369 A HU P0400369A HU P0400369 A2 HUP0400369 A2 HU P0400369A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
carbon atoms
amino
carbon atom
Prior art date
Application number
HU0400369A
Other languages
English (en)
Inventor
Matthew Merrill Hayward
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0400369A2 publication Critical patent/HUP0400369A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)

Abstract

A jelen találmány tárgya eljárás (I) általános képletű vegyület vagygyógyászatilag elfogadható sójának előállítására, ahol a jelentése 0-5közötti egész szám; b jelentése 0-2 közötti egész szám; c jelentése 0-2 közötti egész szám; d jelentése 0-4 közötti egész szám; X jelentése-O-, -S-, -CH2-, -NR6-; Y jelentése 6-10 szénatomos aril- vagy 2-9szénatomos heteroarilcsoport; mindegyik R1 jelentése egymástólfüggetlenül H-, hidroxilcsoport, halogénatom, 1-6 szénatomosalkilcsoport, amely adott esetben 1-3 fluoratommal szubsztituált, 1-8szénatomos alkil-O-csoport, ahol az alkilcsoport adott esetben 1-3fluoratommal szubsztituált, 1-8 szénatomos hidroxi-alkil-, ciano-,amino-; 1-8 szénatomos alkil-amino-, HO-(C=O)-, 1-8 szénatomos alkil-(C=O)-, (1-8 szénatomos alkil)-(C=O)-(1-8 szénatomos alkil)-, H2N-(C=O)-, H2N-(C=O)-(1-8 szénatomos alkil-csoport); mindegyik R2 és R3egymástól függetlenül lehet hidrogénatom, oxo-, 1-8 szénatomosalkilcsoport, amely adott esetben 1-8 fluoratommal szubsztituált, 1-8szénatomos alkil-, 6-10 szénatomos aril-, (6-10 szénatomos aril)-(1-8szénatomos alkil)-, hidroxi-(1-8 szénatomos alkil)-, (1-8 szénatomosalkoxi)-(1-8 szénatomos alkil)-, amino-(1-8 szénatomos alkil)-, (1-8szénatomos alkil)-NH-(1-8 szénatomos alkil)-, (1-8 szénatomosalkil)2N-(1-8 szénatomos alkil)-, (2-9 szénatomos heterociklusos)-(1-8szénatomos alkil)-, (1-8 szénatomos alkil)-(C=O)-NH-(1-8 szénatomosalkil)-, (1-8 szénatomos alkoxi)-(C=O)-NH-(1-8 szénatomos alkil)-,amino-(C=O)-NH-(1-8 szénatomos alkil)-, (1-8 szénatomos alkil)-SO2-NH-(1-8 szénatomos alkil)-, (2-9 szénatomos heteroaril)(1-8 szénatomosalkil)-, amino-(C=0)- vagy amino-(C=O)-(18 szénatomos alkil)-csoport;és mindegyik R4 jelentése egymástól függetlenül hidrogénatom,hidroxilcsoport, halogénatom, ciano-, HO-(C=O)-, amino-, (1-8szénatomos alkil)-NH-, (1-8 szénatomos alkil)2N-, 1-8 szénatomosalkilcsoport, amely adott esetben szubsztituálva lehet 1-3fluoratommal, 1-8 szénatomos alkoxicsoport, ahol az alkilcsoport adottesetben szubsztituált 1-3 fluoratommal, 1-8 szénatomos hidroxi-alkil-,(1-8 szénatomos alkoxi)-(1-8 szénatomos alkil)-, amino-(1-8 szénatomosalkil)-, (1-8 szénatomos alkil)-NH-(1-8 szénatomos alkil)-, (1-8szénatomos alkil)2N-(1-8 szénatomos alkil)-, (1-8 szénatomos alkil)-(C=O)-, (1-8 szénatomos alkil)-(C=O)-(1-8 szénatomos alkil)-, 6-10szénatomos aril-, 2-9 szénatomos heteroaril-, 6-10 szénatomos aril-oxi-, H2N-(C=O)-, H2N-(C=O)-(1-8 szénatomos alkil)-, (1-8 szénatomosalkil)-NH-(C=O)-, (1-8 szénatomos alkil)-NH-(C=O)-(1-8 szénatomosalkil)-, (1-8 szénatomos alkil)2N-(C=O)-, (1-8 szénatomos alkil)2N-(C=O)-(1-8 szénatomos alkil)-, 3-8 szénatomos cikloalkil-, (1-8szénatomos alkil)-SO2-, NC-(1-8 szénatomos alkil)-, (1-8 szénatomosalkil)-(C=O)-NH-, H2N-(C=O)-NH-, H2N-(C=O)-NH-(1-8 szénatomos alkil)-csoport; R5 jelentése 1-8 szénatomos alkilcsaport. A v
HU0400369A 2001-06-20 2002-04-18 Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények HUP0400369A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29946101P 2001-06-20 2001-06-20
PCT/IB2002/001403 WO2002102787A2 (en) 2001-06-20 2002-04-18 Novel sulfonic acid derivatives

Publications (1)

Publication Number Publication Date
HUP0400369A2 true HUP0400369A2 (hu) 2004-12-28

Family

ID=23154893

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400369A HUP0400369A2 (hu) 2001-06-20 2002-04-18 Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények

Country Status (35)

Country Link
US (2) US6974817B2 (hu)
EP (1) EP1430041A2 (hu)
JP (2) JP3829136B2 (hu)
KR (1) KR20040012956A (hu)
CN (1) CN1529699A (hu)
AP (1) AP1564A (hu)
AR (1) AR036094A1 (hu)
BG (1) BG108426A (hu)
BR (1) BR0210531A (hu)
CA (1) CA2447865C (hu)
CZ (1) CZ20033455A3 (hu)
DO (1) DOP2002000399A (hu)
EA (1) EA006447B1 (hu)
EC (1) ECSP034917A (hu)
EE (1) EE200400023A (hu)
GT (1) GT200200095A (hu)
HR (1) HRP20030834A2 (hu)
HU (1) HUP0400369A2 (hu)
IL (1) IL158461A0 (hu)
IS (1) IS6987A (hu)
MA (1) MA27033A1 (hu)
MX (1) MXPA03011954A (hu)
NO (1) NO20035694D0 (hu)
OA (1) OA12623A (hu)
PA (1) PA8548501A1 (hu)
PE (1) PE20030127A1 (hu)
PL (1) PL366900A1 (hu)
SK (1) SK15722003A3 (hu)
SV (1) SV2003001099A (hu)
TN (1) TNSN03140A1 (hu)
UA (1) UA74266C2 (hu)
UY (1) UY27338A1 (hu)
WO (1) WO2002102787A2 (hu)
YU (1) YU94103A (hu)
ZA (1) ZA200307736B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529699A (zh) * 2001-06-20 2004-09-15 �Ʒ� 新的磺酸衍生物
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
SI1957073T1 (sl) 2005-12-05 2014-08-29 Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan Medicinsko zdravilo
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US8716235B2 (en) * 2012-04-18 2014-05-06 Albert Einstein College Of Medicine Of Yeshiva University Method for inhibiting metastasis by using anti-CCL3 antibodies
FR3029112A1 (fr) * 2014-12-02 2016-06-03 Pf Medicament Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (hu) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
KR20020084273A (ko) * 2000-03-31 2002-11-04 화이자 프로덕츠 인코포레이티드 신규한 피페라진 유도체
EA200300392A1 (ru) 2000-10-19 2003-10-30 Пфайзер Продактс Инк. Производные пиперазина с мостиковой связью
CN1529699A (zh) * 2001-06-20 2004-09-15 �Ʒ� 新的磺酸衍生物

Also Published As

Publication number Publication date
DOP2002000399A (es) 2002-12-30
EA200301276A1 (ru) 2004-04-29
PE20030127A1 (es) 2003-02-22
CN1529699A (zh) 2004-09-15
KR20040012956A (ko) 2004-02-11
ZA200307736B (en) 2004-10-04
CZ20033455A3 (en) 2004-06-16
UA74266C2 (uk) 2005-11-15
CA2447865A1 (en) 2002-12-27
AP2002002560A0 (en) 2002-06-30
ECSP034917A (es) 2004-02-26
JP2006232846A (ja) 2006-09-07
HRP20030834A2 (en) 2004-08-31
JP2005511486A (ja) 2005-04-28
CA2447865C (en) 2010-07-20
TNSN03140A1 (fr) 2005-12-23
EE200400023A (et) 2004-06-15
AP1564A (en) 2006-02-02
EP1430041A2 (en) 2004-06-23
US20050250790A1 (en) 2005-11-10
US6974817B2 (en) 2005-12-13
IS6987A (is) 2003-10-09
IL158461A0 (en) 2004-05-12
OA12623A (en) 2006-06-12
NO20035694D0 (no) 2003-12-19
UY27338A1 (es) 2003-10-31
BR0210531A (pt) 2004-06-22
MA27033A1 (fr) 2004-12-20
EA006447B1 (ru) 2005-12-29
WO2002102787A3 (en) 2004-04-29
JP3829136B2 (ja) 2006-10-04
BG108426A (en) 2005-01-31
GT200200095A (es) 2003-02-27
PL366900A1 (en) 2005-02-07
AR036094A1 (es) 2004-08-11
MXPA03011954A (es) 2004-03-26
SK15722003A3 (sk) 2004-08-03
WO2002102787A2 (en) 2002-12-27
PA8548501A1 (es) 2003-05-14
YU94103A (sh) 2006-03-03
SV2003001099A (es) 2003-03-18
US20030083335A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
HUP0400369A2 (hu) Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények
PT870765E (pt) Derivados de aminotiazole drogas contendo os mesmos e intermediarios na producao dos compostos
CA2036876A1 (fr) Derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0799833T3 (da) Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
IL97049A0 (en) Aryl-and heteroarylethenylene derivatives,their preparation and pharmaceutical compositions containing them
ES541709A0 (es) Un procedimiento para la preparacion de derivados de fenoxi-c3-c7-alquiloxi-3,4-dihidro-2h-1-benzopirano
DK616388D0 (da) Quinolincarboxylsyre-derivater og fysiologisk acceptable salte deraf med antibakteriel virkning
DE69223827D1 (de) Glycyrrheticsäurederivate
ES2000604A6 (es) Un procedimiento para preparar aril-piperidin esteres
PT101077A (pt) Processo para a preparacao de derivados de tiazolidinodiona susbtituidos
AU553840B2 (en) Octahydrobenzo(f)quinoline compounds
ES2013403A6 (es) Procedimiento para preparar derivados de cefem.
PT82897B (pt) Processo de preparacao de derivados de di-hidropiridazinona
ES8504723A1 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolonas.
ATE232528T1 (de) Pyrimidinylpyrazolderivate
KR840003646A (ko) 20-아미노틸로신 유도체의 제조방법
PT89120A (pt) Processo para a preparacao de novos derivados flavonoides 2-piperazinil-2-oxo-etileno substituidos
EP0806413A4 (en) 2-SUBSTITUTED VITAMIN D3 DERIVATIVES
NO890440L (no) Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
IS3590A7 (is) Aðferð við framleiðslu á efnasambandinu Indenoindoles II
CA2355098A1 (en) Chroman derivatives
AU598229B2 (en) Novel indenothiazole derivatives and process for their preparation
IE862707L (en) Dichloroaniline derivatives
SE8802428D0 (sv) New compounds
ATE217311T1 (de) Cyclopropancyclus enthaltende purinderivate

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees